The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.
Chatenoud
L
L
INSERM U 25, Hôpital Necker, Paris, France.
Ferran
C
C
Bach
J F
JF
D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D017252:CD3 Complex; D016207:Cytokines / Q000378:metabolism*; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D016207:Cytokines; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma